IVIM & OLINK in Sarcoma
Recruiting now Phase 2 NCT05950594
Run by University Health Network, Toronto · for 18 to 100 · All sexes
What this study is about
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥ 18 years
- Ability to understand and the willingness to sign a written informed consent document
- Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension
🚫 You may not be able to join if…
- Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Where this trial is running
- University Health Network, Toronto, Ontario, Canada
Who to contact
David Shultz, MD · 416-946-4501 · david.shultz@rmp.uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05950594.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.